Core Viewpoint - The announcement details the adjustment of the conversion price for "Meinuo Convertible Bonds" due to the company's 2024 annual profit distribution plan, which includes a cash dividend of 0.05 yuan per share [1][2]. Summary by Sections 1. Convertible Bond Information - The "Meinuo Convertible Bonds" were issued on January 14, 2021, with a total value of 520 million yuan, consisting of 5.2 million bonds, each with a face value of 100 yuan, and a maturity of 6 years [1]. - The initial conversion price was set at 37.47 yuan per share, with the conversion period from July 20, 2021, to January 13, 2027 [2]. 2. Price Adjustment Basis - The adjustment of the conversion price is based on the company's decision made during the 2024 annual shareholders' meeting on May 8, 2025, to distribute a cash dividend of 0.05 yuan per share [2]. - The total share capital will be adjusted accordingly to maintain the distribution ratio despite changes due to convertible bond conversions, share buybacks, or other corporate actions [2]. 3. Conversion Price Adjustment Formula - The adjustment formula for the conversion price is defined in the prospectus, which states that if the company distributes stock dividends, issues new shares, or pays cash dividends, the conversion price will be adjusted accordingly [3][4]. - The specific formula for cash dividend adjustment is P1 = P0 - D, where P0 is the previous conversion price, and D is the cash dividend per share [4]. 4. Adjusted Conversion Price - The conversion price has been adjusted from 25.73 yuan per share to 25.68 yuan per share due to the cash dividend distribution [4]. - The new conversion price will take effect from June 25, 2025, after the suspension of conversion on June 17, 2025 [1][4].

转债代码：113618 转债简称：美诺转债 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 本次利润分配以方案实施前的公司总股本219,828,267股为基数（截至 2025 年 5 月 28 日），每股派发现金红利0.05元（含税），共计派发现金红利10,991,413.35 元（含税）。如截至权益分派股权登记日期间，因可转债转股/回购股份/股权激励 授予股份回购注销/重大资产重组股份回购注销等致使公司总股本发生变动的，公 司拟维持每股分配比例不变，相应调整分配总额。实际权益分派结果以中国证券 登记结算有限责任公司核算的结果为准。 三、相关日期 | | | 四、分配实施办法 证券代码：603538 证券简称：美诺华 公告编号：2025-077 （2）对于持有公司有限售条件流通股的个人股东，根据《关于实施上市公司 ? 每股分配比例 A 股每股现金红利0.05元（含税） ...

Group 1: Macro Overview - The 2025 Lujiazui Forum focused on "Financial Openness and High-Quality Development in the Context of Global Economic Changes," highlighting global financial governance, extensive financial openness, capital market support for technological innovation, and a comprehensive foreign exchange innovation policy [2][11]. - The forum emphasized the need for international financial organizations to enhance the representation of emerging markets and developing countries, and to innovate structural monetary policy tools [3][11]. Group 2: Financial System and Openness - China's financial high-level openness has vast prospects, focusing on expanding consumer demand, promoting fintech, strengthening green finance, and enhancing pension finance [3][12]. - The report outlines ten facilitation policies for foreign exchange management, aiming to create a more convenient, open, secure, and intelligent foreign exchange management system [4][13]. Group 3: Capital Market and Technology Innovation - The introduction of the "1+6" policy measures aims to deepen reforms in the Sci-Tech Innovation Board, including the establishment of a growth layer for unprofitable companies and the introduction of seasoned professional investors [4][5][29]. - The report indicates that the Sci-Tech Innovation Board will support a broader range of sectors, including artificial intelligence and commercial aerospace, enhancing the financing pathways for high-quality tech companies [6][29]. Group 4: IPO and Market Dynamics - The IPO approval process has accelerated, with 19 companies accepted for listing in 2025, signaling a positive trend for new listings [7][29]. - The report notes that the introduction of a third listing standard on the ChiNext board is expected to facilitate the listing of unprofitable companies and those from the Guangdong-Hong Kong-Macao Greater Bay Area [7][29]. Group 5: Industry Insights - The railway investment in China showed a year-on-year growth of 5.9% from January to May 2025, indicating a stable investment environment in the railway sector [18][19]. - The pharmaceutical industry is experiencing a favorable policy environment, with multiple departments issuing supportive measures for innovative drug development [21][22]. Group 6: Company-Specific Updates - Meinuo's revenue from the formulation business is expected to grow significantly, with a projected increase of 84% in 2024, driven by new product registrations and strategic partnerships [35][36]. - Didi's financial outlook remains positive, with projected net profits of 53.52 billion RMB for 2025, reflecting stable demand and improved profitability in international operations [39][40].

宁波美诺华药业股份有限公司（以下简称"公司"）因实施 2024 年度权益分 派,调整"美诺转债"转股价格。 "美诺转债"调整前转股价格：25.73 元/股 | 证券代码：603538 | 证券简称：美诺华 | 公告编号：2025-078 | | --- | --- | --- | | 转债代码：113618 | 转债简称：美诺转债 | | 宁波美诺华药业股份有限公司 关于权益分派引起的"美诺转债"转股价格调整的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券停复牌情况：适用 "美诺转债"调整后转股价格：25.68 元/股 "美诺转债"转股价格调整起始日期：2025 年 6 月 25 日 "美诺转债"2025 年 6 月 17 日停止转股，2025 年 6 月 25 日起恢复转股 | 证券代码 | 证券简称 | 停复牌类型 | 停牌起始日 | 停牌 | 停牌 | 复牌日 | | --- | --- | --- | --- | --- | --- | --- | | | | | | 期间 | 终止日 | ...

| 证券代码：603538 | 证券简称：美诺华 | 公告编号：2025-079 | | --- | --- | --- | | 转债代码：113618 | 转债简称：美诺转债 | | 宁波美诺华药业股份有限公司 3、规格：按沙库巴曲缬沙坦计：100mg（沙库巴曲 49mg/缬沙坦 51mg） 4、申请事项：药品注册（境内生产） 关于全资子公司获得沙库巴曲缬沙坦钠片 药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 宁波美诺华药业股份有限公司（以下简称"公司"）全资子公司宁波美诺华 天康药业有限公司（以下简称"美诺华天康"）于近日收到国家药品监督管理局 （以下简称"国家药监局"）核准签发的沙库巴曲缬沙坦钠片《药品注册证书》， 现将相关情况公告如下： 一、药品相关信息 （一）沙库巴曲缬沙坦钠片 100mg 1、药品名称：沙库巴曲缬沙坦钠片 2、剂型：片剂 5、注册分类：化学药品 4 类 6、受理号：CYHS2400275 7、药品批准文号：国药准字 H20254480 8、药品批准文号有效期：至 2030 年 ...

| 证券代码：603538 | 证券简称：美诺华 | 公告编号：2025-077 | | --- | --- | --- | | 转债代码：113618 | 转债简称：美诺转债 | | 宁波美诺华药业股份有限公司2024年年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 A 股每股现金红利0.05元（含税） 公司本次权益分派不涉及派送红股或转增股本 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/6/24 | － | 2025/6/25 | 2025/6/25 | 差异化分红送转： 否 一、通过分配方案的股东大会届次和日期 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 3. 分配方案： 本次利润分配以方案实施前的公司总股本219,828,267股 ...

Core Viewpoint - Ningbo Meinuo Pharmaceutical Co., Ltd. announced the suspension of the conversion of its convertible bonds "Meinuo Convertible Bonds" during the implementation of the 2024 annual equity distribution, along with an adjustment to the conversion price [1][4]. Group 1: Equity Distribution Plan - The company plans to distribute a cash dividend of 0.05 yuan (including tax) per share based on the total share capital of 219,828,267 shares as of May 28, 2025 [2][4]. - The actual results of the equity distribution will be determined based on the calculations by China Securities Depository and Clearing Corporation Limited [2]. - The equity distribution plan has been approved in meetings held on April 17, 2025, and May 8, 2025 [3]. Group 2: Suspension of Conversion - The "Meinuo Convertible Bonds" will stop conversion from June 17, 2025, until the equity distribution registration date, with resumption of conversion on the first trading day after the registration date [4]. - Holders of "Meinuo Convertible Bonds" wishing to enjoy the equity distribution must convert their bonds by June 16, 2025 [4]. Group 3: Communication - The company will disclose the implementation announcement of the 2024 annual equity distribution and the adjustment of the conversion price on June 18, 2025 [4]. - Contact information for the board office is provided for further inquiries [4].

| 证券代码：603538 | 证券简称：美诺华 | 公告编号：2025-076 | | --- | --- | --- | | 转债代码：113618 | 转债简称：美诺转债 | | 宁波美诺华药业股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券停复牌情况：适用 宁波美诺华药业股份有限公司（以下简称"公司"）因实施 2024 年度权益分 派,本公司的相关证券停复牌情况如下：披露 2024 年度权益分派实施公告前一交 易日（2025 年 6 月 17 日）至本次权益分派股权登记日期间，公司公开发行的可转 换公司债券 "美诺转债"（转债代码：113618）将停止转股。 | 证券代码 | 证券简称 | 停复牌类型 | 停牌起始日 | 停牌 | 停牌 | 复牌日 | | --- | --- | --- | --- | --- | --- | --- | | | | | | 期间 | 终止日 | | | 113618 | 美诺转债 | 可转债转股停牌 | 2025/6/17 | | | | 一、本次权 ...

| 证券代码：603538 | 证券简称：美诺华 | 公告编号：2025-073 | | --- | --- | --- | | 转债代码：113618 | 转债简称：美诺转债 | | 宁波美诺华药业股份有限公司 关于调整公司 2021 年股票期权与限制性股票激励计划 股票期权行权价格的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 2025 年 6 月 10 日，宁波美诺华药业股份有限公司（以下简称"公司"）召 开第五届董事会第十五次会议、第五届监事会第十五次会议，分别审议通过了《关 于调整公司 2021 年股票期权与限制性股票激励计划股票期权行权价格的议案》， 具体情况如下： 一、公司 2021 年股票期权与限制性股票激励计划基本情况 （一）本次激励计划已履行的审议程序和信息披露情况 1、2021 年 11 月 18 日，公司召开第四届董事会第五次会议，审议通过了《关 于<宁波美诺华药业股份有限公司 2021 年股票期权与限制性股票激励计划（草 案）及其摘要>的议案》、《关于<宁波美诺华药业股份有限公司 2021 年 ...

| 证券代码：603538 | 证券简称：美诺华 | 公告编号：2025-074 | | --- | --- | --- | | 转债代码：113618 | 转债简称：美诺转债 | | 宁波美诺华药业股份有限公司 关于 2024 年限制性股票激励计划 首次授予第一个解除限售条件成就的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次符合解除限售条件的激励对象：共计 332 人 本次限制性股票解除限售数量：共2,077,920股，占目前公司总股本的0.95%。 本次解除限售事宜需在有关机构办理相关手续后方可解除限售，届时公司将 另行公告，敬请投资者注意。 （http://www.sse.com.cn/）及相关指定媒体披露的《2023 年年度股东大会决 议公告》。 根据《宁波美诺华药业股份有限公司 2024 年限制性股票激励计划（草案）》 （以下简称 "《激励计划》"）的相关规定和宁波美诺华药业股份有限公司（以下 简称"公司"）2023 年年度股东大会的授权，公司于 2025 年 6 月 10 日召开第五 ...